• CEO interview: Growth Strategy of Shionogi

What's New

  • Show All
2018/10/18
Shionogi Establishes New Manufacturing Subsidiary in Japan
2018/10/18
Shionogi to Announce Corporate Personnel Reassignment
2018/10/12
Shionogi Received “2018 Award for Excellence in Corporate Disclosure” From the Securities Analysts Association of Japan (SAAJ)
2018/10/10
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2018/10/04
Shionogi Presents Positive Results for Baloxavir Marboxil Phase III Study (CAPSTONE-2) in Individuals at High Risk for Influenza-Related Complications at IDWeek 2018
2018/09/28
Shionogi to Present Data on Cefiderocol and Baloxavir Marboxil at IDWeek 2018
2018/09/13
Shionogi and Rohto Pharmaceutical Co.,Ltd. Enter into Lisence Agreement regarding “Cellular and Tissue-based Products” Candidate ADR-001
2018/09/12
Shionogi to Announce Corporate Reorganization and Personnel Reassignment
2018/09/10
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
2018/09/07
The Dispute with the Boards of Appeal of the Japanese Patent Office between MSD regarding HIV Integrase Inhibitor
2018/09/06
Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine
2018/08/31
Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure
2018/08/10
Shionogi Submits New Drug Application of INTUNIV® in Japan for Treatment of Adult ADHD